midscapular region, and an osmotic mini-pump (Alzet model 2004; DURECT Corporation) was implanted. Pumps contained Ang II (Sigma-Aldrich, USA), which was dissolved in saline solution, and the infusion rate was 1.5 mg/kg per day for 4 weeks.
Swimming Exercise-Induced Physiological Cardiac Hypertrophy
Swimming exercise was performed as described. 8 In brief, the swimming-trained mice were subjected to a 90-minute swimming exercise session, twice a day, 5 days a week for 4 weeks. Water temperature was controlled at 30°C to 32°C.
Ang II-Induced Cardiomyocyte Hypertrophy In Vitro
Cardiomyocytes were isolated from 1-to 3-day-old neonatal rat hearts. Ang II treatment was used to induce cardiomyocyte hypertrophy. In the experiments of using Ang II, cardiomyocytes were incubated with 10 nmol/L and 100 nmol/L Ang II for 48 hours. The culture medium containing Ang II was changed every 24 hours. Cardiomyocytes were prepared for immunocytochemistry as described previously. 7 Detailed information is described in the online-only Data Supplement.
Results

BMP4 Expression Increases in Pathological Cardiac Hypertrophy In Vivo and In Vitro
Pressure-overload for 2 and 4 weeks induced significant cardiac hypertrophy ( Figure S1A and S1B in the online-only Data Supplement). The mature and precursor of BMP4 protein and BMP4 mRNA expression were markedly increased in 2-and 4-week TAC-treated hearts ( Figure 1A-1D) . After 1-, 3-, and 7-day TAC treatment, no morphological cardiac hypertrophy was observed in TAC treated mice ( Figure S2A and S2B). However, the BMP4 mature and precursor protein levels increased gradually during the time course ( Figure 1E ), in parallel with the gradual increase of β-myosin heavy chain protein level ( Figure 1F ). Constant release of Ang II by using Alzet pump induced cardiac hypertrophy ( Figure S3A and S3B), in which BMP4 mRNA and protein expressions significantly increased ( Figure 1G and 1H) . Next, the changes of BMP4 expression in an in vitro pathological cardiomyocyte hypertrophy model were examined. Ang II 
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Ctrl (10 nmol/L) treatment for 48 hours induced significant cardiomyocyte hypertrophy ( Figure S4) ; meanwhile, it also induced increases of BMP4 expression in mRNA and protein levels ( Figure 1I and 1J ). Taken together, BMP4 expression increased in pathological cardiac hypertrophy.
To indentify the specificity of BMP4 increase in pathological cardiac hypertrophy, we used the mice ramp swimmingexercise model. 8 After 4-week swimming exercise, mild cardiac hypertrophy was induced without alterations of pathological gene markers such as atrial natriuretic peptide (ANP), B-type natriuretic peptide (BNP), and β-myosin heavy chain ( Figure S5A-S5C) , and without detectable difference in fibrosis ( Figure S12 ). The cardioprotective gene Hsp70 was reported to be upregulated in exercise-induced (physiological) but not in pressure overload-induced (pathological) cardiac hypertrophy. 9 In the present work, Hsp70 protein expression increased in swimming exercise but not in TAC model ( Figure  S5D ). Hence, we concluded that the present swimming exercise-induced cardiac hypertrophy was physiological. No changes of BMP4 mRNA and protein expressions occurred in this model ( Figure S5E and S5F), indicating that BMP4 increase was specific in pathological cardiac hypertrophy.
BMP4 Induces Cardiomyocyte Hypertrophy and Apoptosis Through Increasing NADPH Oxidase 4 Expression and Reactive Oxygen Species-Dependent Pathways
We exposed cultured cardiomyocytes to BMP4 in the presence and absence of BMP4 inhibitor noggin. Cardiomyocytes demonstrated a dramatic increase in size and sarcomeric assembly after 48-hour exposure to 10 and 50 ng/mL BMP4. In the presence of 100 ng/mL noggin, the increases of cell area induced by 50 ng/mL BMP4 were inhibited ( Figure 2A ). BMP4 (50 ng/mL) induced significant increases of ANP, BNP, β-myosin heavy chain mRNA expressions, and protein/DNA ratio, and these increases were reduced by the treatment of BMP4 inhibitors, noggin (100 ng/mL) and DMH1(10 µmol/L; Figure 2B ). We also proved that BMP4-induced cardiomyocyte death ( Figure 2C ) increased caspase-3 activity ( Figure 2D ), increased bax, and decreased bcl-2 protein expression ( Figure 2E ), and these changes were reversed by cotreatment with noggin or DMH1. BMP4 inhibitors alone showed no significant effect on cardiomyocyte hypertrophy, viability, and apoptosis ( Figure  S6 ). Taken together, BMP4 induced not only cardiomyocyte hypertrophy, but also cardiomyocyte apoptosis.
Ang II induced cardiomyocyte hypertrophy and increased expression of ANP and BNP in mRNA level ( Figure 2 F and 2G ). BMP4 inhibitors, noggin, and DMH1 completely suppressed Ang II-induced hypertrophy and Ang II-induced increase of BMP4 mRNA expression ( Figure 2F and 2G), suggesting that BMP4 also mediated Ang II-induced consequences.
Excessive production of reactive oxygen species (ROS) plays an important role in pathological cardiac hypertrophy. 10 We found that BMP4 increased ROS production in cardiomyocytes and the increase was inhibited by DMH1 treatment ( Figure 3A ). NADPH oxidase (NOX) 2 and NOX4 are closely related to ROS production in cardiomyocytes. BMP4 treatment for 48 hours increased NOX4 but not NOX2 mRNA expression (Figure 3B ), and the BMP4-induced increase of NOX4 mRNA expression was inhibited by noggin or DMH1 treatment ( Figure 3C ). BMP4 increased mitochondrial NOX4 protein level, which was inhibited by the treatment of noggin or DMH1, but BMP4 did not affect NOX2 protein level ( Figure 3D ). In in vivo pathological and physiological cardiac hypertrophy models, we found that NOX2 protein expression increased in swimming exerciseinduced cardiac hypertrophy but not in TAC-or Ang IIinduced cardiac hypertrophy ( Figure S7A ). NOX4 protein expression increased in all 3 hypertrophy models ( Figure  S7B ). It was notable that the fold increase of NOX4 in TACand Ang II-induced cardiac hypertrophy was much higher than that in swimming exercise-induced cardiac hypertrophy (3.16±0.553 folds in TAC and 2.75±0.258 folds in Ang II treatment groups versus 1.23±0.023 folds in swimmingexercise group, P<0.01). Next, we further validated the role of NOX4 in BMP4-induced cardiomyocyte hypertrophy and apoptosis by using the NADPH oxidase inhibitor apocynin and the radical scavenger tempol ( Figure S8 ).
Calcineurin and Ca 2+ /calmodulin-dependent protein kinase II (CaMKII), the 2 Ca 2+ -dependent signaling proteins, have been implicated in pathological cardiac hypertrophy. 11, 12 BMP4 treatment did not change calcineurin, CaMKII, phosphorylated CaMKII ( Figure S9A and S9B), as well as total p38, phosphorylated p38, total 1/2ERKs, and phosphorylated 1/2ERKs expressions in protein level ( Figure S9D ). However, BMP4 treatment increased oxidized CaMKII (ox-CaMKII) and phosphorylated JNK (P-JNK) in protein level and the increases were inhibited by noggin or DMH1 treatment ( Figure S9C and S9E). Oxidation-dependent CaMKII activation plays critical role in cardiac hypertrophy and cardiac injury. 13, 14 Both ox-CaMKII and JNK activation are dependent on ROS, [13] [14] [15] therefore we concluded that BMP-induced pathological cardiac hypertrophy was through ROS-dependent pathways.
BMP4-induced cardiomyocyte hypertrophy and apoptosis were further validated by lentivirus-mediated overexpression of BMP4 in cultured cardiomyocytes ( Figure S10 ).
In cardiomyocytes, BMP4-induced increase of BMP4 mRNA was inhibited by noggin treatment ( Figure S11A ). BMP4-induced increase of BMP4 protein expression was suppressed by noggin or DMH1 treatment ( Figure S11B ). BMP2 and BMP4 share >80% amino acid homology and form a distinct subclass of BMPs. Several studies revealed that there was interaction between BMP2 and BMP4. 16, 17 We found that BMP4 treatment did not affect BMP2 protein expression in cardiomyocytes ( Figure S11C ).
BMP4 Induces Cardiac Fibrosis
Pressure-overload and Ang II constant infusion but not swimming exercise induced significant cardiac fibrosis ( Figure S12 ). So we further investigated the role of BMP4 in cardiac fibrosis. BMP4 at 10 and 50 ng/mL showed no effect on cell viability of cardiac fibroblasts ( Figure 4A ). Exposure to 10 and 50 ng/mL BMP4 induced significant increase of collagen in cardiac fibroblasts. In the presence of 100 ng/mL noggin, BMP4-induced increase of collagen was inhibited ( Figure 4B ). BMP4 increased BMP4 protein expression in cardiac fibroblasts ( Figure 4C ).
By immunostaining of α-SMA, the marker of myofibroblasts, we found that BMP4 induced fibroblasts to differentiate into myofibroblasts, which showed not only the clear fiber, but also the enlarged area, and the induced differentiation was inhibited by noggin or DMH1 treatment ( Figure 4D ). Differentiated myofibroblasts were further validated by measuring α-SMA protein expression ( Figure 4E ). However, BMP4 treatment showed no significant effect on matrix metalloproteinase-2 and matrix metalloproteinase-9 mRNA expression in cardiac fibroblasts ( Figure S13 ).
Ang II stimulates fibroblasts to generate collagen and differentiate to myofibroblasts. Ang II treatment increased BMP4 protein expression ( Figure 4F ) and collagen production in cardiac fibroblasts, and the increased collagen was inhibited by noggin or DMH1 treatment ( Figure 4G ). Immunostaining of α-SMA showed that the induced differentiation of myofibroblasts 
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by Ang II was inhibited by noggin or DMH1 treatment ( Figure  4H ), and the detection of α-SMA protein expression showed similar results ( Figure 4I ). In cardiac fibroblasts, apocynin and tempol also inhibited BMP4-induced increase of α-SMA protein expression ( Figure S14 ), indicating that NOX was involved in BMP4-induced fibroblast differentiation.
DMH1 Inhibits Pressure Overload-Induced Pathological Cardiac Hypertrophy In Vivo
Alzet pump containing the small molecule chemical DMH1 was implanted subcutaneously in mice after TAC operation. The rate of constant release of DMH1 was 2 mg/kg per day for 4 weeks. Administration of DMH1 completely suppressed TAC-induced cardiac hypertrophy and fibrosis, as demonstrated by the decreased heart weight/body weight index, left ventricle weight/body weight index, ANP, BNP, β-myosin heavy chain mRNA expressions, myocyte cross section area, fibrosis ratio, collagen I, and NOX4 levels ( Figure 5A -5E). DMH1 treatment inhibited TAC-induced increases of BMP4 and ox-CaMKII in protein level ( Figure 5F and 5G).
Plasma BMP4 Level in Heart Failure Patients
Finally, we examined the plasma BMP4 levels in heart failure patients. The plasma BMP4 level of heart failure patients was increased compared with that of subjects without heart failure ( Figure S15 ).
Discussion
Our data indicated that BMP4 was not only a pathological marker, but also an essential mediator for pathological cardiac hypertrophy. The underlying mechanism of BMP4-induced pathological cardiac hypertrophy was summarized in Figure 6 . We suggest that BMP4 is a novel therapeutic target for pathological cardiac hypertrophy. Several studies about BMP4 in cardiovascular system have implied that BMP4 might be involved in pathological cardiac hypertrophy, for example, BMP4 stimulates ROS production through NADPH oxidases in endothelium, 5, 18 exaggerates cardiac ischemia-reperfusion injury by promoting cardiomyocytes apoptosis. 6 However, the role of BMP4 in pathological cardiac hypertrophy has never been identified. We found that BMP4 induced cardiomyocyte hypertrophy and apoptosis through increasing NOX4 expression and ROS-dependent pathways. There might be multiple ROS-dependent pathways involved in pathological cardiac hypertrophy. In the present work, we measured the p-JNK and ox-CaMKII expressions, but we did not 
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BMP4(50ng/ml) Noggin(100ng/ml) Both NOX2 and NOX4 have been reported to be involved in pathological cardiac hypertrophy. 19 We found that BMP4 treatment increased NOX4 but not NOX2 expression in x200 x200 x200 x200 x200 x200 . Bone morphogenetic protein-4 (BMP4) induces cardiac fibrosis. A, BMP4 (10, 50 ng/mL) had no effect on viability of cardiac fibroblasts. n=6. B, BMP4-induced increase of collagen production in cardiac fibroblasts and the increase was inhibited by noggin. n=5, *P<0.05, **P<0.01 vs control; ##P<0.01 vs 50 ng/mL BMP4. C, BMP4 increased BMP4 protein expression in cardiac fibroblasts. n=8, **P<0.01 vs control. D, BMP4 induced fibroblasts to differentiate into myofibroblasts and the differentiation was inhibited by BMP4 blockers noggin and DMH1. Fibroblasts were immunostained for smooth muscle α-actin (SMA) (red) and nuclei (blue). BMP4-treated fibroblasts had clearly visible SMA positive stress fibers. The framed area was enlarged as shown. Five hundred cells were analyzed for myofibroblast differentiation ratio in each group. χ 2 -test was used, **P<0.005, vs control; ##P<0.005 vs BMP4. E, BMP4 increased α-SMA protein expression in cardiac fibroblasts and the increase was inhibited by cotreatment of noggin or DMH1. n=7, *P<0.05 vs control; #P<0.05 vs BMP4. F, Angiotensin (Ang) II treatment increased BMP4 protein expression in cultured cardiac fibroblasts. n=7, *P<0.05, **P<0.01 vs control. G, BMP4 inhibitors noggin and DMH1 inhibited Ang II-induced collagen increase in cardiac fibroblasts. n=5, **P<0.01 vs control; ##P<0.01 vs Ang II. H, Ang II-induced differentiation from fibroblasts into myofibroblasts was inhibited by BMP4 blockers noggin and DMH1. The framed area was enlarged as shown. One thousand cells were analyzed for myofibroblast differentiation ratio in each group. χ 2 test was used, **P<0.005 vs control; ##P<0.005 vs Ang II. I, The increased α-SMA protein expression induced by Ang II was inhibited by BMP4 blockers noggin and DMH1. n=6, **P<0.01 vs control; ##P<0.01 vs Ang II. cardiomyocytes. Therefore, we further compared NOX2 and NOX4 expressions in in vivo pathological and physiological cardiac hypertrophy models in mice. Results showed that the alterations of NOX4 and NOX2 expressions in in vivo pathological cardiac hypertrophy were consistent with the effects of BMP4 on NOX4 and NOX2 expressions in vitro, indicating that NOX4 played a more important role in pathological cardiac hypertrophy.
We observed the changes of BMP4 expression in TACand Ang II constant infusion-induced cardiac hypertrophy in mice in vivo. TAC treatment increases left ventricular end-systolic pressure, left ventricular end-systolic volume, and left ventricular end-diastolic volume. 20 In this model, the upregulated BMP4 expression in the heart might come from the local pressure and volume overload. Ang II shows multiple effects, such as increase of the systemic blood pressure, increase of sympathetic activity, and increase of Ang II-aldosterone system. Therefore, in Ang II constant infusioninduced cardiac hypertrophy model, we extrapolated that the upregulated BMP4 expression might come from the pressureoverload and the direct stimulation of hormones. A recent work reported that BMP4 was involved in valvular interstitial cell activation in human myxomatous mitral valve prolapse. 21 They found that in vitro hBMP4 treatment of isolated human mitral valvular interstitial cells mimicked the cellular activation and extracellular matrix remodeling as seen in mitral valve prolapse tissues. Mitral valve prolapse was associated with development to progressive mitral regurgitation, which in turn, predisposed to eccentric left ventricular hypertrophy. Our data together with this report indicated that BMP4 mediated not only the pathological cardiac hypertrophy, but also the mitral valve prolapse, suggesting that BMP4 might be a target with wide clinic potential.
Heart failure is generally accompanied with endothelial dysfunction. 22 Therefore, in addition to the heart, the increased plasma BMP4 in heart failure patients may also come from the injured endothelium, from which BMP4 can also be secreted. 23 Because BMP4 induced cardiac hypertrophy, apoptosis, and fibrosis, the increased plasma BMP4 might be an important factor to promote human heart failure progress.
Perspectives
BMP4 induces pathological cardiac hypertrophy. Furthermore, BMP4 upregulates itself, which magnifies the harmful effects of BMP4. Therefore, blockade of BMP4 and its related signaling is of therapeutic significance. It is exciting that the small molecule BMP4 inhibitor such as DMH1 has been developed, which make it promising to develop the kind of small molecule chemicals for clinic. 
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Supplemental Methods Agents
Angiotensin Ⅱ(AngⅡ) and DMH1 were purchased from Sigma (sigma-Aldrich); Tempol was purchased from Santa Cruz Biotechnology and PhosSTOP from Roche; Anti-BMP-4, -BMP-2, -CaMKII, -NOX-4 and -NOX-2(gp-91) antibodies were from Santa Cruz; Anti-p-CAMK-Ⅱwas from Promega; Anti-calcineurin was from BD Biosciences; Anti-HSP-70,-Bax and -Bcl-2 were from Cell signaling Technology. Anti-GAPDH was from kangchen (China). Anti-sarcomeric α-actinin was from Abcam. Anti-β-MHC was form Sigma. Anti-p-P38, anti-P38, anti-p-ERK1/2, anti-ERK1/2, anti-p-JNK, anti-JNK were from cell signaling technology. Anti-ox-CaMKII was from Millipore. Recombinant human BMP-4, BMP-2 and recombinant human noggin were purchased from R&D Systems. The real-time PCR primers were shown in Table-S1 .
Animals
Kunming mice (male) and Wistar rats (SLAC Laboratory Animal Co. Ltd, Shanghai, China) were used. The animals were kept under standard animal room conditions (temperature 21±1 °C; humidity 55-60%) with food and water continuously available for 1 week before the experiment. All the experimental procedures were approved by the Institutional Animal Care and Use Committee of Harbin Medical University, PR China.
Pressure Overload-induced Cardiac Hypertrophy in vivo
The pressure-overload heart hypertrophy models were obtained by subjecting the animals to transverse aortic constriction (TAC) as described in our previous work 1 . Adult male mice (22-26g body weight) were anesthetized and placed in the supine position and a midline cervical incision was made to expose the trachea. After successful endotracheal intubation, the cannula was connected to a volume cycled rodent ventilator (UGO BASILE S.R.L. Italy). The chest was opened and the thoracic aorta was identified. A 7-0 silk suture was placed around the transverse aorta and tied around a 26-gauge blunt needle which was subsequently removed. This maneuvers increased systolic pressure about 1.5 folds and induced cardiac hypertrophy (1). The chest was closed and the animals were kept ventilated until recovery of autonomic breath. At the pre-determined time points (day 1,3,7 and week 2,4), surviving animals were sacrificed and the heart was quickly excised and weighted in cold (4°C) buffer. The left ventricle and right ventricle were separated and weighted, and left ventricle tissue was then rapidly frozen in liquid nitrogen and stored at -80°C for subsequent western blot or real-time PCR analysis. All procedures involving animals and their care were approved by the Institutional Animal Care and Use Committee of Harbin Medical University, PR China.
Angiotensin II (Ang II)-induced cardiac hypertrophy in vivo
Male mice (22-26g body weight) were anesthetized with sodium pentobarbital (60 mg/kg, i.p.). A 1-cm incision was prepared in the mid-scapular region and an osmotic mini-pump (Alzet model 2004; DURECT Corporation) was implanted. Pumps contained Ang II (Sigma-Aldrich, USA) which was dissolved in saline solution and the infusion rate was 1.5 mg/kg per day. After 4 weeks, mice were sacrificed, hearts were weighted and left cardiac ventricles (LCV) were fixed in 10% formalin for histology or quickly frozen in liquid nitrogen for quantification of gene expression.
Swimming exercise-induced physiological cardiac hypertrophy
Swimming exercise was carried out as described 2 . In brief, the swimming-trained mice were subjected to a 90-min swimming exercise session, twice a day, 5 days a week for 4 weeks.
Water temperature was controlled at 30-32°C. Angiotensin II-induced cardiomyocyte hypertrophy in vitro Ang II treatment was used to induce cardiomyocyte hypertrophy. In the experiments of using Ang II, cardiomyocytes were incubated with 10nmol/L and 100nmol/L AngⅡ for 48hrs. The culture media containing AngⅡwas changed every 24 hrs. Cardiomyocytes were prepared for immunocytochemistry as described previously 1 . Monoclonal antibody against sarcomeric α-actinin (Sigma) was added at dilutions of 1:200. Nuclear staining was performed with 1.3μmol/L bisbenzimide (Sigma). The cardiomyocyte surface was depicted by using Image-Pro Plus Version (5.0.1) software and the relative surface area was read with the arbitrary units (the number of pixels) for evaluating hypertrophy 1 .
Isolation and culture of cardiomyocyte and cardiac fibroblast
Cardiomyocytes and cardiac fibroblasts were isolated from 1-3-day-old neonatal rat hearts using a conventional method adopted by our and other studies 1, 3 . Briefly, after hearts were digested by trypsin, cells were suspended in DMEM (Dulbecco's modified Eagle's medium/medium) with 10 %FBS, and pre-cultured in humidified incubator (95%air-5% CO 2 ) for 90 min to obtain cardiac fibroblasts for their selective adhesion. Then the suspended cardiomyocytes were plated in another dish. The purity of cardiomyocytes was increased by supplementing BrdU(5-Bromo-2'-deoxyuridine) to prevent non-cardiomyocytes from developing. Culture medium was renewed after 48hrs and cells were further cultured for 24hrs. Then, both cardiomyocytes and cardiac fibroblasts were cultured in non-serum DMEM for 12hrs before experiments. Protein/ DNA Ratio Analysis After standard culture procedures, the total protein and DNA ratio of cardiomyocytes was analyzed. In a brief, cells were rinsed in cold PBS twice and scraped with 100ul of lysis buffer (150mM Nacl ,15mM sodium citrate and 0.25%SDS PH=7.0).The collected cells were immediately frozen and stored at -20℃. Then samples were thawed and vortexed, 1ul sample was applied to determine the total protein content using BCA method. DNA concentrations were detected by using a DNA Quantitation Kit (Sigma-Aldrich).
BMP4 inhibitor DMH1 treatment in vivo
After TAC operation, 1-cm incision was prepared in the mid-scapular region of mice and an osmotic mini-pump (Alzet model 2004; Alza) containing DMH1(Sigma-Aldrich,USA)was implanted. The constant infusion rate of DMH1 was 2 mg/kg per day. After 4 weeks, mice were sacrificed and hearts were harvested for analysis.
Drug treatment
Ang ( 10nmol/L and 100nmol/L Ⅱ ), BMP4 (50ng/ml), BMP2(50ng/ml), Noggin (100ng/ml ) and DMH1(10μmol/L) were applied for 24hrs in cardiac fibroblasts and 48hrs in cardiomyocytes. The culture media containing different drugs was renewed every 24 hrs. In the experiments, BMP4, BMP2 and noggin were dissolved in PBS solution and diluted in the culture media as the ratio 1.25:5000. DMH1 was dissolved in DMSO and diluted in the culture media as the ratio 0.7:1000. Under this condition, these vehicles showed no effect.
Real-time PCR Analysis
One microgram of total RNA from each sample was used to generate cDNA by using M-MLV reverse transcriptase per manufacturer's specifications (Promega Corporation,USA). Real-time PCR was cycled in 95°C/15s, 60°C/30s and 72°C/30s for 40 cycles, after an initial denaturation step at 95°C for 10 min using SYBR Green PCR Master Mix purchased from Applied Biosystems (USA). Amplification was performed by using 7500 Fast Real-Time PCR Systems (Applied Biosystems,USA) and the products were routinely checked by using dissociation curve software. Transcript quantities were compared by using the relative quantitive method, where the amount of detected mRNA normalized to the amount of endogenous control (GAPDH). The relative value to the control sample is given by 2 -∆∆CT . The real-time PCR primer sequences were shown in Table-S1 . Western Blot Cellular and tissue proteins were extracted with lysis buffer which contained 1% protease inhibitor solution. After complete homogenization on ice rotator, samples were centrifuged at 13500g for 15min at 4 to precipitate cell debris. The supernatants were transferred into ℃ fresh tubes and protein concentrations were determined with BCA Protein Assay Kit(Bio-Rad). The proteins were electrophoresed in 10% SDS-PAGE and transferred to nitrocellulose membranes. After blocking with 5% non-fat dry milk in phosphate-buffered saline (PBS) for 2 hours at room temprature, the membranes were incubated with the primary antibodies at 4 over night. After washing with PBS ℃ -0.1% Tween 20(PBST), membranes were incubated with fluorescence-conjugated goat anti-rabbit IgG , goat anti-mouse IgG or donkey anti-goat IgG (1:10000 dilution, Invitrogen) at room temperature for 1h. Western blot bands were quantified by using Odyssey infrared imaging system (LI-COR) and Odyssey v3.0 software.
MTT assay
Viability of cells cultured in the 96-well culture plates was assessed by measuring mitochondrial dehydrogenase activity, using the colorimetric MTT assay, based on the fact that viable cells (but not dead cells) can reduce 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT).
Collagen assay
Collagen assay was performed using the Sircol collagen assay method (biocolor, UK). Briefly, 100µl test samples of treated cardiac fibroblasts were mixed with 1ml Sirco dyes reagent and incubated at 25°C for 30 minutes. After centrifugation at 1,0000 g for 10 minutes, the supernatants were removed. Then 1ml alkali regent was added to pellet to release the bound dye into solutions. The absorbance of each sample was measured by a microplate Reader at 540nm. TUNEL staining After 3 times PBS washing, treated myocytes were fixed by 4% paraformaldehyde, permeabilized in 0.1% Triton x-100 sodium citrate buffer. Then an In Stiu cell death detection kits (Roche) were used to label apoptotic cells, and the nuclei were stained with DAPI. The numbers of total cells and Tunel positive cells were automatically counted by Image-Pro plus version. The apoptosis rate was defined as ratio of apoptotic cells to total cells. Detection of reactive oxygen species (ROS) by flow cytometry ROS level of cardiomyocytes was quantified by using ROS assay kit (Beyotime Institute of Biotechnology, China). Cells were harvested by trypsin and exposed for 20 min at 37 ℃ to 10 µmol/L DCFH-DA, which became fluorescent when oxidized to DCF within the cells. Labeled cells were washed twice in PBS and then subject to cytometric analysis (excitation: 488nm; emission:525nm). The model of flow cytometry was FACSAria (BD). ROS level was represented with fluorescence intensity. The number of analyzed cells was 10000 in each individual experiment. Caspase-3 activity assay Caspase-3 activity was determined by using Caspase-3 Activity Assay Kit (Beyotime Institute of Biotechnology, China), which is based on the ability of caspase-3 to change acetyl-Asp-Glu-Val-Asp p-nitroanilide (Ac-DEVD-pNA) into the yellow formazan product, p-nitroaniline (pNA). Briefly, the cells were harvested and washed with cool PBS twice,then the cells were lysed with lysis buffer (100µl per 2×106cells) for 15 min on ice. The lysate was centrifuged at 13500r/min for 15 min at 4 °C, then collected the supernatant and protein concentration was determined by Bradford Protein Assay Kit (Beyotime Institute of Biotechnology, China). After incubating the mixture composed of 40µl of cell lysate, 50µl reaction buffer and 10µl of 2mmol caspase-3 substrate(Ac-DEVD-pNA)in 96-well plates at 37℃ overnight, the absorbance of p-nitroanilide at 405nm was determined by using a microtiter plate reader (Bio-TEK Epoch, BioTek Instrument, VT,USA). Caspase-3 activity was calculated as a ratio of p-nitroanilide content to total protein amount. The detail analysis procedure was described in the manufacturer's protocol (Beyotime Institute of Biotechnology, China).
Infection of cardiomyocytes with lentiviruses expressing rBMP4
Cardiomoyotes were plated in 6 wells plate(2×10 5 cells /well) and cultured in a humidified incubator (95% air-5% CO 2 ) at 37°C. After 48hrs incubation, culture medium was renewed and cells were further cultured for 24hrs. Then, the cells were prepared for lentivirus infection with rBMP4 lentiviral packaging prepared by 3DBiopharm Co Ltd (Shanghai, China) which was shown in Figure-S10A . Infection was carried out in DMEM with 10% FBS at MOI (multiplicity of infection) of 20 for 48hrs to obtain the maximal efficiency and the minimal cell loss. Polybrene (6µg/ml) was added to ensure the infection efficiency. After 48hrs infection, culture medium was changed to the medium without lentiviruses and the cells were further cultured for 24hrs. BMP4 overexpression induced by rBMP4 lentiviral transfection was confirmed by western blot examination (Figure-S10B ). The performance of lentiviral transfection was based on the company's instruction.
Plasma BMP4 measurement
The human plasma BMP4 concentration was measured with BMP4 human Elisa Kit (Abcam Inc, USA) according to the specifications.
Plasma samples
The plasma collection was approved by the Ethics Committee of Harbin Medical University. The plasma samples of heart failure patients were provided by the cardiology department, first affiliated hospital of Harbin Medical University. The control plasma samples were provided by the clinical laboratory, the second affiliated hospital, Harbin Medical University. The control plasma samples were from subjects of department of ENT (ear-nose-throat) when the routine blood index checks were finished. The residual plasma was used for the present study. The subjects as control were without heart diseases. The age of subjects as control (57.0±2.0 years) matched with the heart failure patients (63.2±2.5 years) as possible. The plasma fraction was prepared immediately by centrifugation at 3,000g for 5 min at 4 . ℃ Samples were then immediately divided into aliquots (0.5 ml) in cryovials and frozen at -80 until the analysis procedures were carried out. The information of ℃ subjects as control was shown in Table-S2 , and the clinical parameters of heart failure patients were shown in Table-S3 . Data analysis Data were presented as mean±SEM. Significance was determined by using Student t test or one-way ANOVA, followed by Tukey post test. P<0.05 was considered significant. . Noggin and DMH1 alone showed no effect on cardiomyocyte hypertrophy, viability and apoptosis. A. Noggin and DMH1 alone showed no effect on cardiomyocyte hypertrophy. For cell area evaluation, fifty cells were qualified in each group from three individual experiments. n=8 for ANP, BNP, β-MHC mRNA expression analysis. B. Cell viability was examined by MTT method. n=3 individual experiments. C. Noggin and DMH1 showed no effect on caspase-3 activity in cardiomyocytes. n=3 individual experiments. D. Noggin and DMH1 showed no effect on ROS production in cardiomyocytes. n=4 individual experiments. E. Noggin and DMH1 showed no effect on cardiomyocyte apoptosis evaluated by TUNEL staining. . BMP4 treatment increased ox-CaMKII, P-JNK but did not alter calcineurin, CaMKII, P-CaMKII, P-p38,total-p38, P-ERK1/2 and total ERK1/2 in protein level in cultured cardiomyocytes. A. Representative westernblots and analyzed data for calcineurin in cultured cardiomyocytes.Cal, calcineurin. B. Representative westernblots and analyzed data for total CaMKII, phosphorylated CaMKII (P-CaMKII) in cultured cardiomyocytes. C. Representative westernblots and analyzed data for ox-CaMKII in cultured cardiomyocytes. X200 X200 X200 X200 X200 X200 X200 X200 X200 X200 X200
transfection was confirmed in two independent experiments. C. BMP4 overexpression by rBMP4 lentiviral transfection induced cardiomyocyte hypertrophy. The cell area and hypertrophy markers were evaluated. For evaluation of cardiomyocyte area, 250 cells from two independent experiments in each group were analyzed. n=8 for analysis of ANP, BNP, β-MHC mRNA expression. **P<0.01, vs. control. D. TUNEL staining assay showed that BMP4 overexpression by rBMP4 lentiviral transfection induced cardiomyocyte apoptosis. TUNEL-positive nuclei are green, and DAPI is blue. The number of cells from two independent experiments was shown in the brackets. X 2 -test was used, **P<0.005, vs. control. Figure S11 . BMP4 induced increase of BMP4 expression in cultured cardiomyocytes. A. BMP4 induced increase of BMP4 mRNA expression was inhibited by noggin treatment. n=6,**P<0.01, vs. control; ## P< 0.01 vs.50ng/ml BMP4. B. BMP4 induced increase of BMP4 protein expression was inhibited by noggin and DMH1 treatment. n=7, **P<0.01, vs. control; ## P< 0.01 vs.50ng/ml BMP4. C. BMP4 did not affect cardiac BMP2 protein expression in cardiomyocytes. n=4. Figure S12 . TAC or Ang II constant infusion but not swimming-exercise induced cardiac fibrosis in mice. Cardiac fibrosis was analyzed and quantified by using masson's trichrome method. The interstitial fibrosis was in blue staining. The degree of fibrosis was evaluated by the ratio of the area of blue staining to the total area. Image-Pro Plus Version (5.0.1) was used for analysis. A. Representative fields of Masson's trichrome stained heart sections in each groups. TAC and Ang II-treated animals showed more perivascular fibrosis in the hearts. B.
The summarized data showed that TAC and Ang II, but not swimming exercise induced significant cardiac fibrosis. n=10. **P<0.01 vs Sham or control.
A B Figure S13 . BMP4 treatment had no significant effect on matrix metalloproteinase-2 (MMP-2) and MMP-9 mRNA expressions in cardiac fibroblasts. n=6 in each group. Figure S14 . The increased α-SMA protein expression induced by BMP4 was inhibited by apocynin and tempol. n=6, **P<0.01, vs. control; #P< 0.05 vs. BMP4. Figure S15 . Plasma BMP4 level increased in heart failure patients. Compared with control, the plasma BMP4 levels were increased in heart failure patients.
